
|Videos|July 13, 2016
William Oh, MD: Biggest Considerations for Elderly Patient Population
Advertisement
What are the biggest considerations and concerns in an elderly patient?
CASE: Metastatic Prostate Cancer (Part 1)
Stanley S is an 83-year-old Caucasian male whose past medical history includes diagnosis of adenocarcinoma of the prostate in 2012 with no evidence of metastasis. At the time, he was started on bicalutamide and his serum PSA levels subsequently decreased to 1.2 ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- His serum PSA level is 56.9 ng/ml and his alkaline phosphatase is 258 U/L
- CT scan shows enlarged lumbar bone metastasis with associated soft tissue component, as well as symptomatic nodes with lumbar bone metastases
- Biopsies of the prostate and transrectal ultrasound reveal the prostate is 42 grams
- Ten of 14 cores are positive for prostate cancer for a Gleason score of 8 (4 + 4)
- His ECOG performance status score is a 2
Advertisement
Related to this article

Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
4
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
5










